Pfizer Inc. (NYSE:PFE)

Stock Price: $43.76

-0.4 (-0.91%)

Updated Sep 30, 2022 08:03 PM GMT+0000

Featured app

Invest now

68% of retail CFD accounts lose money

Overview

Financials

Statistics

Profile

Chart

Market Cap	245.60B
Revenue	101.13B
Gross Profit	62.94B
Shares Out	5.61B
EPS (ttm)	5.11
PE Ratio	8.4559
Forward PE	6.8153
Dividend Rate (ttm)	1.5716
Dividend Yield	0.0356

Trading Day	Sep 30
Last Price	$43.76
Previous Close	$44.16
Change ($)	-0.4
Change (%)	-0.91%
Day's Open	44.2
Day's Range	43.73 - 44.605
Day's Volume	22.96M
52 Week Range	39.64 - 60.28

About Pfizer

Pfizer applies science and its global resources to bring therapies to people that extend and significantly improve their lives. It strives to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines.

Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with its responsibility as one of the world's premier innovative biopharmaceutical companies, it collaborates with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world.

For more than 150 years, it has worked to make a difference for all who rely on it. It routinely posts information that may be important to investors on its website at www.Pfizer.com.

NYSE:PFE stock is currently trading at $43.76 as of 08:03 PM UTC, Sep 30, 2022. Use the financials tab to find out more about Pfizer's key financial metrics and recent earnings reports, or track its share price in real time on the chart tab. If you would like to buy shares in Pfizer, our detailed guide explains how to buy Pfizer stock.

News

Pfizer is acquiring Global Blood Therapeutics August 9, 2022

This biotech stock is up 100% on Tuesday: here’s the catalyst June 21, 2022

Here is why Biohaven Pharmaceuticals soared 70% May 13, 2022

Pfizer lowers earnings guidance despite a solid Q1 May 3, 2022

Myovant Sciences provides an update on a supplemental new drug April 16, 2022

Is Moderna a better buy compared to Pfizer? March 28, 2022

Should you buy Pfizer shares? March 7, 2022

Pfizer v Medical Properties: Covid-19 Vaccines give Pfizer an edge February 19, 2022

Pfizer tops fourth-quarter EPS by $0.20 February 8, 2022

Is Pfizer stock a buy or sell after the FDA’s rejection sparked a stock sell-off? January 25, 2022

Quick info

Country

United States

Industry

Pharmaceutical Preparation Manufacturing

Sector

Manufacturing

Employees

78,500

CEO

Albert Bourla

Address

235 E 42nd St
New York
New York
10017-5703

Phone

12125732323

Website

www.pfizer.com

Ticker Symbol

PFE

Exchange

New York Stock Exchange

Reporting Currency

USD

Pfizer Inc. income statements (2022) (USD)

	August 2022
Total Revenue	27.74B
Cost of Revenue	8.65B
Gross Profit	19.09B
Research & Development	2.82B
Selling General & Admin	3.05B
Operating Expense	15.33B
Operating Income	12.41B
Other Income Expense Net	222M
EBIT	12.78B
Interest Income	263M
Pretax Income	11.45B
Income Tax	1.57B
Minority Interest	6M
Net Income	9.91B
Net Income Basic	9.91B

Pfizer Inc. income statements (2021) (USD)

	November 2021
Total Revenue	24.09B
Cost of Revenue	9.97B
Gross Profit	14.12B
Research & Development	3.45B
Selling General & Admin	2.91B
Operating Expense	17.31B
Operating Income	6.79B
Other Income Expense Net	326M
EBIT	7.22B
Interest Income	315M
Pretax Income	7.84B
Income Tax	-331M
Minority Interest	12M
Net Income	8.15B
Net Income Basic	8.15B

Pfizer Inc. income statements (2020) (USD)

	November 2020	June 2020	June 2020	March 2020
Total Revenue	12.13B	11.80B	11.80B	12.03B
Cost of Revenue	2.53B	3.17B	3.17B	3.25B
Gross Profit	9.60B	8.63B	8.63B	8.78B
Research & Development	2.36B	2.13B	2.13B	1.73B
Selling General & Admin	3.02B	2.97B	2.97B	2.86B
Operating Expense	8.80B	8.27B	8.27B	7.84B
Operating Income	3.33B	3.53B	3.53B	4.19B
Other Income Expense Net	0	419M	419M	-308M
EBIT	3.33B	3.53B	3.53B	4.19B
Interest Income	0	372M	372M	390M
Pretax Income	2.18B	3.95B	3.95B	3.89B
Income Tax	-26M	519M	519M	475M
Minority Interest	8M	8M	8M	9M
Net Income	2.19B	3.43B	3.43B	3.40B
Net Income Basic	2.19B	3.43B	3.43B	3.40B

Pfizer Inc. income statements (2019) (USD)

	December 2019	September 2019	June 2019	March 2019
Total Revenue	12.69B	12.68B	13.26B	13.12B
Cost of Revenue	3.62B	3.79B	3.74B	3.59B
Gross Profit	9.07B	8.89B	9.53B	9.52B
Research & Development	2.81B	2.28B	1.83B	1.70B
Selling General & Admin	4.21B	3.24B	3.49B	3.33B
Operating Expense	10.64B	9.31B	9.06B	8.62B
Operating Income	2.04B	3.37B	4.20B	4.50B
Other Income Expense Net	-3.55B	7.36B	-62M	-176M
EBIT	2.04B	3.37B	4.20B	4.50B
Interest Income	415M	409M	389M	361M
Pretax Income	-1.51B	10.73B	4.14B	4.32B
Income Tax	-1.18B	3.05B	-0.92B	433M
Minority Interest	10M	4M	10M	6M
Net Income	-337M	7.68B	5.05B	3.88B
Net Income Basic	-337M	7.68B	5.05B	3.88B

Pfizer Inc. income statements (2018) (USD)

	December 2018	September 2018	June 2018	March 2018
Total Revenue	13.98B	13.30B	13.47B	12.91B
Cost of Revenue	4.30B	3.93B	4.09B	3.73B
Gross Profit	9.68B	9.37B	9.38B	9.18B
Research & Development	2.44B	2B	1.79B	1.74B
Selling General & Admin	3.99B	3.48B	3.53B	3.40B
Operating Expense	10.72B	9.40B	9.40B	8.86B
Operating Income	3.26B	3.90B	4.06B	4.05B
Other Income Expense Net	-4.2B	281M	464M	79M
EBIT	3.26B	3.90B	4.06B	4.05B
Interest Income	370M	310M	326M	310M
Pretax Income	-0.95B	4.18B	4.53B	4.13B
Income Tax	-563M	66M	648M	556M
Minority Interest	11M	8M	7M	9M
Net Income	-394M	4.11B	3.87B	3.56B
Net Income Basic	-394M	4.11B	3.87B	3.56B

Pfizer Inc. income statements (2017) (USD)

	December 2017	September 2017	June 2017
Total Revenue	13.70B	13.17B	12.90B
Cost of Revenue	4.39B	3.96B	3.81B
Gross Profit	9.32B	9.21B	9.08B
Research & Development	2.30B	1.85B	1.77B
Selling General & Admin	4.53B	3.48B	3.41B
Operating Expense	11.21B	9.29B	8.99B
Operating Income	2.49B	3.88B	3.90B
Other Income Expense Net	-1.54B	-296M	-88M
EBIT	2.49B	3.88B	3.90B
Interest Income	329M	320M	312M
Pretax Income	0.95B	3.59B	3.82B
Income Tax	-11.34B	727M	739M
Minority Interest	15M	18M	5M
Net Income	12.27B	2.84B	3.07B
Net Income Basic	12.27B	2.84B	3.07B

Pfizer Inc. balance sheet (2022) (USD)

	August 2022
Current Cash	33.30B
Receivables	15.16B
Inventory	10.45B
Current Assets	67.47B
Other Current Assets	8.55B
Short Term Investments	8.55B
Long Term Investments	127.82B
Property/Plant Equipment	15.24B
Good Will	N.A
Intangible Assets	29.07B
Tangible Assets (Net)	8.25B
Other Assets	14.66B
Total Assets	195.29B
Accounts Payable	6.21B
Other Current Liabilities	35.21B
Total Current Liabilities	47.41B
Total Liabilities	108.08B
Long Term Debt	34.29B
Current Long Term Debt	5.99B
Minority Interest	261M
Common Stock	5.59B
Treasury Stock	-113.94B
Retained Earnings	116.61B
Capital Surplus	N.A
Shareholder Equity	87.21B
Other Liabilities	N.A

Pfizer Inc. balance sheet (2021) (USD)

	November 2021	November 2021
Current Cash	29.70B	29.70B
Receivables	11.90B	11.90B
Inventory	8.64B	8.64B
Current Assets	57.90B	57.90B
Other Current Assets	7.67B	7.67B
Short Term Investments	7.67B	7.67B
Long Term Investments	121.29B	121.29B
Property/Plant Equipment	14.44B	14.44B
Good Will	N.A	N.A
Intangible Assets	26.31B	26.31B
Tangible Assets (Net)	-104M	-104M
Other Assets	9.46B	9.46B
Total Assets	179.19B	179.19B
Accounts Payable	4.70B	4.70B
Other Current Liabilities	33.48B	33.48B
Total Current Liabilities	41.80B	41.80B
Total Liabilities	103.50B	103.50B
Long Term Debt	36.25B	36.25B
Current Long Term Debt	3.63B	3.63B
Minority Interest	275M	275M
Common Stock	5.61B	5.61B
Treasury Stock	-111.36B	-111.36B
Retained Earnings	102.25B	102.25B
Capital Surplus	N.A	N.A
Shareholder Equity	75.69B	75.69B
Other Liabilities	N.A	N.A

Pfizer Inc. balance sheet (2020) (USD)

	November 2020	June 2020	March 2020
Current Cash	10.50B	1.80B	2.15B
Receivables	10.01B	9.13B	9.88B
Inventory	9.30B	8.56B	8.42B
Current Assets	47.74B	46.42B	34.74B
Other Current Assets	6.52B	5.94B	6.08B
Short Term Investments	6.52B	20.99B	8.20B
Long Term Investments	131.24B	18.72B	18.22B
Property/Plant Equipment	14.40B	14.11B	14.04B
Good Will	N.A	N.A	N.A
Intangible Assets	30.93B	33.54B	34.46B
Tangible Assets (Net)	-25.57B	-152.77B	-152.18B
Other Assets	7B	4.33B	4.17B
Total Assets	178.98B	177.93B	166.34B
Accounts Payable	4.14B	3.87B	3.97B
Other Current Liabilities	16.65B	14.32B	12.76B
Total Current Liabilities	34.15B	32.72B	33.89B
Total Liabilities	113.73B	113.37B	101B
Long Term Debt	49.79B	50.53B	36.28B
Current Long Term Debt	13.36B	1.48B	337M
Minority Interest	236M	8M	9M
Common Stock	88.63B	5.55B	5.55B
Treasury Stock	-110.98B	110.98B	111.01B
Retained Earnings	100.28B	100.20B	101B
Capital Surplus	N.A	87.89B	87.68B
Shareholder Equity	65.26B	64.34B	65.03B
Other Liabilities	N.A	N.A	N.A

Pfizer Inc. balance sheet (2019) (USD)

	December 2019	September 2019	June 2019	March 2019
Current Cash	1.31B	2.79B	1.78B	1.94B
Receivables	8.72B	9.44B	9.79B	9.60B
Inventory	8.28B	8.22B	8.23B	8.03B
Current Assets	32.80B	33.46B	47.07B	45.29B
Other Current Assets	5.97B	6.71B	16.14B	16.04B
Short Term Investments	8.53B	6.30B	11.13B	9.68B
Long Term Investments	20.15B	18.72B	2.91B	2.86B
Property/Plant Equipment	15.28B	15.01B	14.79B	14.75B
Good Will	N.A	N.A	N.A	N.A
Intangible Assets	35.37B	39B	33.02B	34.04B
Tangible Assets (Net)	-154.57B	-155.16B	-142.99B	-143.99B
Other Assets	3.14B	3.61B	3.12B	3.05B
Total Assets	167.49B	170.45B	156.20B	155.42B
Accounts Payable	4.22B	3.94B	4B	4.16B
Other Current Liabilities	15.63B	14.24B	15.72B	13.76B
Total Current Liabilities	37.30B	36.97B	32.03B	29.42B
Total Liabilities	104.04B	105.05B	96.27B	96.26B
Long Term Debt	37B	37.08B	37.19B	36.78B
Current Long Term Debt	1.46B	2.43B	2.14B	4.47B
Minority Interest	10M	4M	10M	6M
Common Stock	5.53B	5.53B	5.56B	5.56B
Treasury Stock	110.80B	110.80B	110.79B	110.78B
Retained Earnings	97.67B	100.11B	94.44B	93.39B
Capital Surplus	87.43B	87.10B	86.96B	86.64B
Shareholder Equity	63.14B	65.10B	59.57B	58.81B
Other Liabilities	N.A	N.A	N.A	N.A

Pfizer Inc. balance sheet (2018) (USD)

	December 2018	September 2018	June 2018	March 2018
Current Cash	1.17B	3.56B	2.70B	2.30B
Receivables	8.03B	10.02B	9.87B	9.45B
Inventory	7.51B	8.18B	8.07B	8.15B
Current Assets	49.93B	41.58B	37.30B	34.84B
Other Current Assets	15.56B	6.14B	5.93B	5.81B
Short Term Investments	17.66B	13.68B	10.73B	9.12B
Long Term Investments	2.77B	6.44B	6.60B	6.95B
Property/Plant Equipment	13.39B	14.04B	13.92B	13.97B
Good Will	N.A	N.A	N.A	N.A
Intangible Assets	35.21B	45.31B	46.58B	47.69B
Tangible Assets (Net)	-139.37B	-145.39B	-147.65B	-148.75B
Other Assets	2.80B	2.98B	2.90B	2.90B
Total Assets	159.42B	167.84B	164.98B	164.61B
Accounts Payable	4.67B	4.30B	4.20B	3.88B
Other Current Liabilities	17.09B	14.55B	13.90B	12.86B
Total Current Liabilities	31.86B	29.01B	32.16B	27.37B
Total Liabilities	95.66B	96.17B	94.86B	94.07B
Long Term Debt	32.91B	33.65B	28.94B	31.83B
Current Long Term Debt	4.78B	4.26B	4.26B	4.76B
Minority Interest	11M	8M	7M	9M
Common Stock	5.72B	5.78B	5.86B	5.85B
Treasury Stock	101.61B	96.57B	95.46B	95.46B
Retained Earnings	89.55B	91.99B	89.86B	89.96B
Capital Surplus	86.25B	85.83B	84.90B	84.60B
Shareholder Equity	63.41B	71.32B	69.78B	70.18B
Other Liabilities	N.A	N.A	N.A	N.A

Pfizer Inc. balance sheet (2017) (USD)

	December 2017	September 2017	June 2017
Current Cash	1.34B	2.78B	2.59B
Receivables	8.22B	10B	9.48B
Inventory	7.58B	7.93B	7.58B
Current Assets	41.14B	40.29B	36.39B
Other Current Assets	5.35B	5.44B	4.99B
Short Term Investments	18.65B	14.15B	11.75B
Long Term Investments	7.02B	7.31B	7.01B
Property/Plant Equipment	13.87B	13.51B	13.39B
Good Will	N.A	N.A	N.A
Intangible Assets	48.74B	49.72B	51.35B
Tangible Assets (Net)	-146.37B	-157.27B	-157.5B
Other Assets	3.23B	3.39B	3.47B
Total Assets	171.80B	172.15B	168.56B
Accounts Payable	4.66B	3.48B	3.44B
Other Current Liabilities	15.34B	14.29B	13.68B
Total Current Liabilities	30.43B	28.22B	27.18B
Total Liabilities	100.14B	111.04B	109.86B
Long Term Debt	33.54B	34.50B	34.19B
Current Long Term Debt	3.55B	3.07B	3.07B
Minority Interest	15M	18M	5M
Common Stock	5.98B	5.96B	5.95B
Treasury Stock	89.43B	89.42B	89.42B
Retained Earnings	85.29B	75.04B	74.11B
Capital Surplus	84.28B	83.83B	83.37B
Shareholder Equity	71.31B	60.77B	58.37B
Other Liabilities	N.A	N.A	N.A

Pfizer Inc. cash flow (2022) (USD)

	August 2022
Net Income	9.91B
Depreciation	1.18B
Changes in Receivables	15.16B
Changes in Inventories	10.45B
Cash Change	33.30B
Cash Flow	8.17B
Capital Expenditures	-751M
Investments	N.A
Investing Activity (other)	N.A
Total Investing Cash Flows	-11.31B
Dividends Paid	N.A
Net Borrowings	-1.57B
Other Financing Cash Flows	N.A
Cash Flow Financing	2.52B
Exchange Rate Effect	N.A

Pfizer Inc. cash flow (2021) (USD)

	November 2021
Net Income	8.15B
Depreciation	1.36B
Changes in Receivables	11.90B
Changes in Inventories	8.64B
Cash Change	29.70B
Cash Flow	10.83B
Capital Expenditures	-1.49B
Investments	N.A
Investing Activity (other)	N.A
Total Investing Cash Flows	-10.08B
Dividends Paid	N.A
Net Borrowings	2.52B
Other Financing Cash Flows	N.A
Cash Flow Financing	-1.1B
Exchange Rate Effect	N.A

Pfizer Inc. cash flow (2020) (USD)

	November 2020	June 2020	March 2020
Net Income	2.19B	3.43B	3.40B
Depreciation	3.73B	1.25B	1.22B
Changes in Receivables	884M	753M	-1.16B
Changes in Inventories	731M	N.A	N.A
Cash Change	-883M	-352M	847M
Cash Flow	8.78B	3.55B	3.13B
Capital Expenditures	-1.51B	-480M	-495M
Investments	N.A	-12.55B	420M
Investing Activity (other)	N.A	N.A	N.A
Total Investing Cash Flows	-12.6B	-13.01B	-71M
Dividends Paid	N.A	-2.11B	-2.11B
Net Borrowings	46.13B	11.32B	18M
Other Financing Cash Flows	N.A	-84M	-237M
Cash Flow Financing	4.14B	9.16B	-2.2B
Exchange Rate Effect	N.A	-55M	-15M

Pfizer Inc. cash flow (2019) (USD)

	December 2019	September 2019	June 2019	March 2019
Net Income	-337M	7.68B	5.05B	3.88B
Depreciation	1.38B	1.55B	1.53B	1.55B
Changes in Receivables	715M	354M	-194M	-1.57B
Changes in Inventories	N.A	N.A	N.A	N.A
Cash Change	-1.5B	1.01B	-182M	793M
Cash Flow	3.77B	4.51B	2.61B	1.70B
Capital Expenditures	-726M	-662M	-588M	-618M
Investments	-2.17B	4.80B	-1.43B	8.10B
Investing Activity (other)	N.A	N.A	N.A	N.A
Total Investing Cash Flows	-2.83B	-6.76B	-1.9B	7.55B
Dividends Paid	-1.99B	-2B	-2B	-2.05B
Net Borrowings	-470M	5.35B	1.07B	2.81B
Other Financing Cash Flows	-69M	-125M	-45M	-496M
Cash Flow Financing	-2.44B	3.27B	-851M	-8.47B
Exchange Rate Effect	9M	-13M	-40M	12M

Pfizer Inc. cash flow (2018) (USD)

	December 2018	September 2018	June 2018	March 2018
Net Income	-394M	4.11B	3.87B	3.56B
Depreciation	1.64B	1.61B	1.56B	1.57B
Changes in Receivables	2B	-151M	-421M	-1.23B
Changes in Inventories	N.A	N.A	N.A	N.A
Cash Change	-2.43B	848M	395M	0.99B
Cash Flow	4.74B	5.26B	3.85B	1.98B
Capital Expenditures	-792M	-562M	-456M	-386M
Investments	-10M	-2.45B	-1.13B	10.03B
Investing Activity (other)	N.A	N.A	N.A	N.A
Total Investing Cash Flows	-764M	-2.9B	-1.47B	9.67B
Dividends Paid	-1.96B	-1.99B	-1.99B	-2.03B
Net Borrowings	462M	790M	316M	-2.5B
Other Financing Cash Flows	-36M	278M	-337M	-494M
Cash Flow Financing	-6.41B	-1.41B	-1.91B	-10.72B
Exchange Rate Effect	N.A	-101M	-70M	55M

Pfizer Inc. cash flow (2017) (USD)

	December 2017	September 2017	June 2017
Net Income	12.27B	2.84B	3.07B
Depreciation	1.57B	1.57B	1.57B
Changes in Receivables	1.78B	-526M	-584M
Changes in Inventories	N.A	N.A	N.A
Cash Change	-1.44B	194M	-1.47B
Cash Flow	6.74B	4.89B	3.25B
Capital Expenditures	-773M	-597M	-489M
Investments	-4.14B	-2.46B	-0.99B
Investing Activity (other)	N.A	N.A	N.A
Total Investing Cash Flows	-4.78B	-3B	-1.74B
Dividends Paid	-1.91B	-1.9B	-1.91B
Net Borrowings	-1.67B	-84M	-1.18B
Other Financing Cash Flows	-10M	5M	-8M
Cash Flow Financing	-3.39B	-1.73B	-3B
Exchange Rate Effect	-14M	30M	16M

Pfizer Inc. dividends (USD)

Ex date	Payment date	Record date	Declared date	Amount	Description	Frequency
28-07-2022	06-09-2022	29-07-2022	N.A	0.40	Ordinary Shares	Quarterly
04-11-2021	06-12-2021	05-11-2021	N.A	0.39	Ordinary Shares	Quarterly
05-11-2020	01-12-2020	06-11-2020	N.A	0.38	Ordinary Shares	Quarterly
30-07-2020	01-09-2020	31-07-2020	N.A	0.38	Ordinary Shares	Quarterly
30-07-2020	01-09-2020	31-07-2020	N.A	0.38	Ordinary Shares	Quarterly
07-05-2020	05-06-2020	08-05-2020	N.A	0.38	Ordinary Shares	Quarterly
30-01-2020	06-03-2020	31-01-2020	N.A	0.38	Ordinary Shares	Quarterly
07-11-2019	02-12-2019	08-11-2019	N.A	0.36	Ordinary Shares	Quarterly
01-08-2019	03-09-2019	02-08-2019	N.A	0.36	Ordinary Shares	Quarterly
09-05-2019	07-06-2019	10-05-2019	N.A	0.36	Ordinary Shares	Quarterly
31-01-2019	01-03-2019	01-02-2019	N.A	0.36	Ordinary Shares	Quarterly
08-11-2018	03-12-2018	09-11-2018	N.A	0.34	Ordinary Shares	Quarterly
02-08-2018	04-09-2018	03-08-2018	N.A	0.34	Ordinary Shares	Quarterly
10-05-2018	01-06-2018	11-05-2018	N.A	0.34	Ordinary Shares	Quarterly
01-02-2018	01-03-2018	02-02-2018	N.A	0.34	Ordinary Shares	Quarterly
09-11-2017	01-12-2017	10-11-2017	N.A	0.32	Ordinary Shares	Quarterly
02-08-2017	01-09-2017	04-08-2017	N.A	0.32	Ordinary Shares	Quarterly
10-05-2017	01-06-2017	12-05-2017	N.A	0.32	Ordinary Shares	Quarterly
01-02-2017	01-03-2017	03-02-2017	N.A	0.32	Ordinary Shares	Quarterly
08-11-2016	01-12-2016	11-11-2016	N.A	0.30	Ordinary Shares	Quarterly
03-08-2016	01-09-2016	05-08-2016	N.A	0.30	Ordinary Shares	Quarterly
11-05-2016	01-06-2016	13-05-2016	N.A	0.30	Ordinary Shares	Quarterly
03-02-2016	02-03-2016	05-02-2016	N.A	0.30	Ordinary Shares	Quarterly
04-11-2015	01-12-2015	06-11-2015	N.A	0.28	Ordinary Shares	Quarterly
05-08-2015	02-09-2015	07-08-2015	N.A	0.28	Ordinary Shares	Quarterly